Scholarlink

Background <p>COVID-19 patients are at increased risk of thrombosis and bleeding, but no standardized bleeding risk assessment tool has been recommended.</p> Objective <p>This study evaluates the predictive value of the IMPROVE Bleeding Risk Score (BRS) in hospitalized COVID-19 patients.</p> Design <p>A multicenter, prospective cohort of 3,886 hospitalized COVID-19 patients across six tertiary hospitals in China between December 1, 2022, and January 31, 2023.</p> Participants <p>Patients were objectively diagnosed with COVID-19 by pathogen or antibody detection and followed for 90&#xa0;days.</p> Main Measures <p>The primary outcomes were major bleeding (MB) and clinically relevant non-major bleeding (CRNMB). We evaluated the IMPROVE BRS predictive performance using hazard ratios (HRs), positive and negative predictive values, the area under the receiver operating characteristic curve (AUC), and calibration.</p> Key Results <p>Among 3,886 hospitalized COVID-19 patients (median age 74, IQR 62–84), 42&#xa0;MB (1.1%) and 47 CRNMB (1.2%) events occurred within 90&#xa0;days. The IMPROVE BRS performed well in predicting MB events, with an AUC of 0.84 (95% CI, 0.77–0.91) at 90&#xa0;days. Calibration plots indicated good calibration. High-risk patients had a significantly higher bleeding risk than low-risk patients, even after adjusting for low molecular weight heparin (LMWH) thromboprophylaxis (MB: adjusted HR 6.63, 95% CI 3.62–12.15; CRNMB: adjusted HR 3.69, 95% CI 2.04–6.71). Subgroup analysis indicated that LMWH thromboprophylaxis significantly increased MB risk in elderly patients with high bleeding risk (14&#xa0;days: adjusted HR 5.45, 95% CI 1.15–25.94; 30&#xa0;days: adjusted HR 4.16, 95% CI 1.11–15.53).</p> Conclusions <p>The IMPROVE BRS effectively predicted MB risk in COVID-19 patients and provided valuable guidance for LMWH thromboprophylaxis in elderly patients. Further research is needed to validate its applicability in different populations and refine threshold values for improved predictive accuracy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

External Validation of the IMPROVE Risk Score for Predicting Bleeding in Hospitalized COVID-19 Patients

  • 期刊论文

  • 发表日期：

    2025年2月20日

查看全文
  • Yuzhi Tao,
  • Feiya Xu,
  • Jing Han,
  • Chaosheng Deng,
  • Rui Liang,
  • Lijun Chen,
  • Binliang Wang,
  • Yunhui Zhang,
  • Weijia Liu,
  • Dingyi Wang,
  • Guohui Fan,
  • Zhaofei Chen,
  • Yinong Chen,
  • Kaiyuan Zhen,
  • Yunxia Zhang,
  • Shuai Zhang,
  • Qiang Huang,
  • Jun Wan,
  • Wanmu Xie,
  • Peiran Yang,
  • Zhu Zhang,
  • Chen Wang,
  • Zhenguo Zhai

摘要

Background

COVID-19 patients are at increased risk of thrombosis and bleeding, but no standardized bleeding risk assessment tool has been recommended.

Objective

This study evaluates the predictive value of the IMPROVE Bleeding Risk Score (BRS) in hospitalized COVID-19 patients.

Design

A multicenter, prospective cohort of 3,886 hospitalized COVID-19 patients across six tertiary hospitals in China between December 1, 2022, and January 31, 2023.

Participants

Patients were objectively diagnosed with COVID-19 by pathogen or antibody detection and followed for 90 days.

Main Measures

The primary outcomes were major bleeding (MB) and clinically relevant non-major bleeding (CRNMB). We evaluated the IMPROVE BRS predictive performance using hazard ratios (HRs), positive and negative predictive values, the area under the receiver operating characteristic curve (AUC), and calibration.

Key Results

Among 3,886 hospitalized COVID-19 patients (median age 74, IQR 62–84), 42 MB (1.1%) and 47 CRNMB (1.2%) events occurred within 90 days. The IMPROVE BRS performed well in predicting MB events, with an AUC of 0.84 (95% CI, 0.77–0.91) at 90 days. Calibration plots indicated good calibration. High-risk patients had a significantly higher bleeding risk than low-risk patients, even after adjusting for low molecular weight heparin (LMWH) thromboprophylaxis (MB: adjusted HR 6.63, 95% CI 3.62–12.15; CRNMB: adjusted HR 3.69, 95% CI 2.04–6.71). Subgroup analysis indicated that LMWH thromboprophylaxis significantly increased MB risk in elderly patients with high bleeding risk (14 days: adjusted HR 5.45, 95% CI 1.15–25.94; 30 days: adjusted HR 4.16, 95% CI 1.11–15.53).

Conclusions

The IMPROVE BRS effectively predicted MB risk in COVID-19 patients and provided valuable guidance for LMWH thromboprophylaxis in elderly patients. Further research is needed to validate its applicability in different populations and refine threshold values for improved predictive accuracy.